ArticleBJUI compass2022
Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centre.
Article in BJUI compass, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07498959 (Testicular Cancer Treatment), which is not on this map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Comparison of Perioperative and Oncologic Outcomes Between Robotic and Open Retroperitoneal Lymph Node Dissection in Testicular Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Robotic assisted versus non-robotic retroperitoneal lymph node dissection for testicular cancer: an updated systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Comparative efficacy and safety of robotic-assisted versus open retroperitoneal lymph node dissection in testicular cancer management: a systematic review and meta-analysis.Journal of robotic surgery · 2025Pooled it
- Clinical efficacy and safety of robotic retroperitoneal lymph node dissection for testicular cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives.Journal of robotic surgery · 2025Review
- [Retroperitoneal lymphadenectomy in the treatment of testicular germ cell tumors-Is the robot-assisted technique superior to the open surgical approach?]Urologie (Heidelberg, Germany) · 2025Review
- The perioperative outcomes of retroperitoneal lymph node dissection in Germany for patients with testicular cancer: Results from the GRAND study.International journal of cancer · 2025Article
- Matched-pair analysis of peri-operative and oncological outcomes of robot-assisted vs open retroperitoneal lymph node dissection.BJU international · 2025Article
- Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer-First Experience and Learning Curve of a Single Surgeon.Cancers · 2025Article
- Article
- Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Current oncology reports · 2024Review
- Unilateral post-chemotherapy robot-assisted retroperitoneal lymph node dissection in Stage II non-seminomatous germ cell tumor: A tertiary care experience.Asian journal of urology · 2023Article
- Comparison of laparoscopic, robotic, and open retroperitoneal lymph node dissection for non-seminomatous germ cell tumor: a single-center retrospective cohort study.World journal of urology · 2023Article
- Red Out: Bleeding During Robotic Retroperitoneal Lymph Node Dissection and Strategies To Manage It.European urology open science · 2023Article
- Shining a little light on peer review debates.BJUI compass · 2022Article
- Robotic retroperitoneal lymph node dissection for testicular cancer at a national referral centre.BJUI compass · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: We aim to determine if robot-assisted retroperitoneal lymph node dissection (R-RPLND) can be performed as a safe option to open RPLND in selected patients with metastatic germ cell cancer. Patients and methods: This population-based prospective study was performed at a one of two national referral centres for RPLND in Sweden. All patients referred during January 2017-March 2021 were screened for possible inclusion. R-RPLND was performed using the Da Vinci Xi surgical system. Perioperative parameters, postoperative complications (Clavien-Dindo), final pathology, preservation of antegrade ejaculation and relapse rates were evaluated. Classifiers for selecting patients to open versus robotic RPLND were analysed by logistic regression modelling. The median follow-up was 23 months. Results: Of 87 patients referred, 29 were selected for R-RPLND, 19 in a post-chemotherapy setting. In median, retroperitoneal tumour diameter was 18 mm, BMI 24 kg/m Conclusion: This population-based study suggests that R-RPLND can be safely performed in at least one third of patients referred for an RPLND. A relatively high rate of lymph-leakage may represent a potential drawback. Tumour size may be the most important discriminator when deciding on robotic versus open RPLND. Further studies with longer follow-up are needed to validate the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.